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1. Introduction 
Breast cancer is one of the most prevalent cancer types among women worldwide (Jemal et 
al., 2011); however, its incidence rates among populations are heterogeneous. Epidemiologic 
studies have shown that breast cancer incidence in Asian women is 40% lower than in 
Caucasian women (Goldin et al., 1986). A reasonable explanation for the difference in the 
cancer incidence rates could be related to intrinsic biological characteristics present in each 
population. For example, in general, breast cancer growth requires the presence of estrogen 
and it is known that Asian women have lower estrogen serum levels than Caucasian women 
(Shimizu et al., 1990). Nevertheless, epidemiologic studies have reported that when Asian 
women moved to western countries the breast cancer incidence of their subsequent 
generations were similar to the Caucasian women (Wu et al., 1996). Therefore, it seems that 
other factors have been influencing breast cancer incidence rates in each population. 
In fact, it is known that only 10-15% of all breast cancers cases are caused by genetic 
predisposition such as BRCA and Li-Fraumeni mutations; whereas the remaining 85-90% of 
cases are attributed to environmental, reproductive, lifestyle factors including radiation, 
chemicals, late pregnancy, early menarche, nulliparity, diet and reduced physical activity 
(Colditz et al., 1995). The diet is an important factor affecting breast cancer incidence rates 
and is estimated to be correlated with 50% of new diagnosed cases (Willett, 1995). It has 
been described that diets based on the consumption of garlic, onion, tomato, vegetables, 
fruits and legumes are associated with reduced breast cancer risk. One of the major 
differences between western and Asian populations is their diet. The consumption of 
legumes (soy, beans, peas) in Asian populations is expressively higher than in western 
populations. These disparities on breast cancer risk and on legume intake have attracted the 
attention of scientists and since then this topic has been the goal of innumerable researches 
(Messina et al., 2006). 
In addition to their importance as a nutritive food source, legumes and their bioactive 
compounds have also been described to show protective and therapeutic effects not only in 
breast cancer, but also in symptoms of menopause, heart disease and osteoporosis. On the 
other hand, findings suggesting no effects or possible risks in legume intake and breast 
cancer have also been published (Messina et al., 2008). Therefore, the evaluation of the 
effects of legume consumption on women at high risk for breast cancer and breast cancer 
patients is an important public health goal (Messina et al., 2006). In this chapter, we provide 
a comprehensive review of the biological, nutritional and economic background on legumes 
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and gather the current knowledge regarding the benefits and risks of their bioactive 
molecules in breast cancer prevention and treatment. 
2. Legumes - biological, nutritional and economic aspects 
The legumes are classified in the family Fabacea (or Leguminosae) – including around 700 
legume genera and 20,000 species – and are the third largest flowering plant family (Doyle 
et al., 2003; Gepts et al., 2005). They present a large range of variation and are also well 
adapted to several temperatures and climates (Doyle et al., 2003). Despite the large number 
of species, only a few legumes are generally known due to their use as feeds and foods. 
Clovers (Trifolium sp.), vetches (Vicia faba) and alfafa (Medicago sativa) are mainly grown for 
animal feeding; while beans (Phaseolus vulgaris), soybeans (Glycine max), lentils (Lens 
esculenta), peas (Pisum sativum), and peanuts (Arachis hypogaea) are the main species grown 
for food (Doyle et al., 2003; Gepts et al., 2005). 
Legumes nutritional profile includes dietary fibers, low glycemic indexes, no cholesterol, 
low levels of fat (2- 5%), and high amounts of carbohydrates (55- 60%). In addition, essential 
minerals and vitamins for human health are also present (Rochfort et al., 2007). High protein 
content (20-40%) is another notable feature of legumes which is known to be 2-3 times 
higher than cereals. Along with their high protein content, they also produce a good balance 
of all essential aminoacids, with the exception of methionine (Rochfort et al., 2007).  
Among legumes, soybeans have not only the highest protein content but also the highest 
protein digestibility, which is typically 90%. Soybeans and peanuts are considered an 
exception among legumes in terms of nutritional profile. Despite producing high protein 
contents, they are low in carbohydrates but high in fat (40% total energy) (Messina et al., 
2010). In addition, soy is a component widely used to fortify school breakfast and lunch 
programs and is also present in upwards 60% of processed foods (Patisaul et al., 2010).  
Some legumes produce antinutritional factors which have shown to induce allergy and 
intestinal disturbance when eaten raw. However, the majority of these toxins can be 
eliminated through heating or other industrially processing (Gepts et al., 2005).  
The intake rates of legumes vary dramatically among populations worldwide. In Asian 
countries, legumes have been consumed for centuries representing ~50% of their diet which 
achieve and even surpass the minimum intake recommended. On the other hand, the rates 
of legume consumption by North American and European countries are low (Messina, 
2010).  
A few decades ago researchers have reported that some compounds produced by legumes 
could promote protective and therapeutic effects on human health. This new vision of 
legumes as functional foods has induced a profound impact in sales and consumption of 
legumes in countries which had low consumption rates as the EUA and European countries 
(Messina et al., 2001; Messina, 2010; Patisaul et al., 2010).  
3. Legume bioactive compounds and breast cancer 
Hypothesis regarding protective and therapeutic effects of legumes in breast cancer have 
been formulated mainly based on epidemiological studies suggesting a negative correlation 
between legume intake and breast cancer incidence among populations worldwide. Asian 
women, who traditionally consume high amounts of legumes daily, are 4 to 10 times less 
likely to be diagnosed with and die from breast cancer than are people in the United States 
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(Fournier et al., 1998). Interestingly, genetic variations do not seem to be the main factors 
involved in this disparity since Asian women who immigrate to the United States and 
adopted a “Western” lifestyle, particularly a diet poor in legumes, develop breast cancer risk 
comparable to Caucasian women within two generations (Wu et al., 1996).  
These evidences have triggered several researches seeking for the identification of potential 
legume molecules involved in breast cancer prevention and treatment.  Isoflavones, protease 
inhibitors and peptides are the main legume bioactive compounds evaluated in this field. In 
the next sections, their anticancer properties as well as synergistic effects are discussed. 
4. Isoflavones 
Legumes produce large amounts and several isoflavones isoforms which are assumed to 
have antimicrobial activity and to play an important role in plant protection (Rochfort et al., 
2007). In particular, soybeans produce 12 isoforms of isoflavones and contain the highest 
dietary-relevant amounts of these compounds among legumes (Franke et al., 1998). For 
example, each gram of soy protein in soybeans contains approximately 3.5 mg of 
isoflavones; while no significant amounts are present in lentils (Murphy et al., 1999). For this 
reason, the majority of published data regarding their activities in breast cancer involve 
isoflavones found in soy.   
4.1 Structural and bioavailability 
The isoflavones are a subclass of flavonoids and belong to the group of naturally occurring 
heterocyclic phenols. Their basic structure is composed of 2 benzene rings linked through a 
heterocyclic pyrane ring. Isoflavones are named glycoside (inactive form) when conjugated 
to glucose or carbohydrate moieties and glycone (active form) when unconjugated (Franke 
et al., 1998) (Fig.1). 
 
 
Fig. 1. Chemical structures of the genistein (4', 5, 7-trihydroxyisoflavone) and daidzein (4', 7-
dihydroxyisoflavone), the most abundant isoflavones found in soy. The figure was drawn 
by ChemDraw (Cambridge Soft, version 9.0). 
The primary isoflavones found in soybeans are the glycones genistein (4’,5,7-
trihydroxyisoflavone), daidzein (4’,7-dihydroxyisoflavone) and glycitein (7,49- dihydroxy-6-
methoxyisoflavone), and their respective glycosides genistin, daidzin and glycitin (Messina 
et al., 2001). Genistein and daidzein are the most abundant isoflavones in soybeans 
representing 50% and 40% of the total isoflavone content respectively (Rochfort et al., 2007).  
The majority of isoflavones found in raw soybeans are almost entirely as glycosides 
(genistin, daidzin, and glycitin) while only 1 – 3% account for their active form glycone 
(Murphy et al., 1999). After ingestion, they are rapidly absorbed entering systemic 
circulation predominantly as conjugated forms (95%) with limited bioavailability (Messina 
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et al., 2006). Isoflavones then are further deconjugated by the action of glucosidases 
produced in intestinal bacteria. Interestingly, there is considerable inter-individual variation 
in intestinal bacteria metabolism of genistein and daidzein. The bioconvertion of daidzein to 
one of its metabolites (equol) is performed by a very specific type of intestinal bacteria 
which have been found only in 30–50% of individuals (Patisaul et al., 2010).   
The resulting isoflavone metabolites are widely biodistributed and their serum levels can 
reach the low micromolar range according to the amount ingested (Messina et al., 2001). Soy 
isoflavones have half-lives of approximately 8 hours and are nearly all excreted within 24 
hours after consumption (Messina et al., 2006). 
4.2 Exploring isoflavones biological effects on breast cancer 
4.2.1 Estrogen-receptor dependent properties 
Breast cancer development is significantly influenced by the exposure to estrogens. These 
hormones have been described to induce proliferation of malignant breast cells contributing 
to breast cancer promotion and progression. Therefore, the control of estrogen exposure is a 
key factor in breast cancer chemoprevention (Bouker et al., 2000).  
The structures of soy isoflavones are similar to mammalian estrogens (Messina et al., 2001). 
By the early 1960s, isoflavones were characterized as ligands of estrogen receptors and thus 
labelled as phytoestrogens (Cheng et al., 1953). These findings led to an initial enthusiasm 
mainly based on the possibility that isoflavones might exert antiestrogenic effects on breast 
tissue as other known estrogen antagonists such as tamoxifen (Messina et al., 2001).  
Folman & Pope were the first to conduct assays establishing the relative binding affinity 
isoflavones for the estrogen receptor (ER) (Folman et al., 1966). There are two major ER 
subtypes in mammals, ER-ǂ and ER-ǃ presenting different tissue distributions. Soy 
isoflavones have singular affinities for each ER and for this reason are classified as selective 
estrogen receptor modulators (SERMs) (Messina et al., 2006). Genistein is 7- to 48-fold more 
selective for ER-ǃ than Er-ǂ and is 1,000-fold more potent at triggering transcriptional 
activity with ER-ǃ than Er-ǂ (Kuiper et al., 1998). However, isoflavones are considered to be 
weak estrogens, showing binding affinity to ER-ǂ and ER-ǃ of nearly 20- and 5-fold less 
than estradiol, respectively (Kuiper et al., 1998). 
There are some evidences suggesting that activation of ER-ǃ inhibits proliferation in breast 
cells (Patisaul et al., 2010). Because genistein preferentially binds to ER-ǃ, it may induce 
antiestrogenic effects through this receptor (Bouker et al., 2000). Moreover, soy isoflavones 
can act as an antiestrogen through other mechanisms. Genistein has the ability to inhibit the 
enzyme 17ǃ-hydroxysteroid oxidoreductase type 1 (HSOR-1), which is necessary for 
estradiol secretion from the ovaries in premenopausal women and is essential for the 
reduction of estrone to estradiol in the adipose tissues. Isoflavones are also involved in the 
inhibition of the aromatase enzyme, which is responsible for the conversion of androgens to 
estrone in peripheral (adipose) tissues (Bouker et al., 2000). Thus, the inhibition of estrogen–
metabolizing enzymes can lead to a decreased total estradiol level and intensify isoflavones 
antiestrogen effects. It is important to highlight that complex feedback mechanisms 
associated with the hypothalamic/ pituitary/gonadal axis are involved in controlling the 
levels of estrogen and that the effects of isoflavones in this network are unclear and demand 
further studies (Bouker et al., 2000).   
The main biological effects of soy isoflavones in breast cancer cells involve cell growth arrest 
and induction of apoptosis (Lamartiniere et al., 1998). Genistein have been shown to inhibit 
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growth factor- and cytokine -stimulated growth of breast cancer cells (Peterson et al., 1996). 
Indeed, at the molecular level, this isoflavone can influence the regulation of cell cycle 
molecules by inducing significant up-regulation of p21/WAF1 expression (cell cycle 
inhibitor) in the treatment of breast cancer cells (Banerjee et al., 2008). In addition, the 
treatment of breast cancer cells with genistein influences the regulation of apoptotic 
molecules such as down-regulating anti-apoptotic molecules (Bcl-2, Bcl-xL, and HER-2/neu) 
and up-regulating pro-apoptotic ones (Bax and caspases). It has been suggested that 
genistein could also induce the regulation of those genes through the inhibition of 
proteasome. Overall, these findings suggest that ER stress, cell cycle arrest and apoptosis 
induction may represent part of the molecular mechanism by which isoflavones exert their 
anticarcinogenic effects (Banerjee et al., 2008).  
4.2.2 Estrogen-receptor independent properties 
Interestingly, the effects of soy isoflavones on cell cycle arrest and apoptosis has been 
detected not only in ER-positive but also in ER-negative breast cancer cells (Theil et al., 2010) 
suggesting that isoflavones anticancer activity might also occur independently of ER 
modulation. Indeed, several non-estrogenic targets for isoflavones have been described.  
Isoflavones have been described as specific inhibitors of protein-tyrosine kinase (PTK), 
which is an enzyme frequently overexpressed in cancer cells. PTKs are crucial molecules for 
tumor development and thus soy isoflavones can potentially slow tumorigenesis by 
inhibiting their mediated signalling mechanisms (Banerjee et al., 2008; Patisaul et al., 2010). 
Isoflavones can modulate and block the activity of several molecules involved in breast 
cancer cell growth and survival pathways such as topoisomerase I and II, mitogen activated 
protein kinases (MAPK), urokinase- type plasminogen activator (uPA), and nuclear factor-
κB (NF-κB). Isoflavones are also implicated in the growth inhibition of various cancer cells 
through the regulation of gene activity by modulating epigenetic events that are intimately 
related to the regulation of cell cycle and apoptosis such as DNA methylation and/or 
histone acetylation (Messina et al., 2001; Banerjee et al., 2008).  
Furthermore, soy isoflavones are able to inhibit invasion, metastasis, and angiogenesis in 
vitro and in vivo in a number of cancers including breast cancer. Genistein was described to 
inhibit the secretion of matrix metalloproteinases (crucial enzymes for invasion and 
metastasis) in MDA-MB-435 breast cancer cells and blocked invasion of a highly meta-static 
subline of BALB/c mammary carcinoma cells (Bouker et al., 2000; Messina et al., 2001). 
Antioxidant activity is also included among the described effects of soy isoflavones. They 
are able to protect cells against reactive oxygen species by scavenging free radicals and 
inhibiting the expression of stress–response related genes which is an interesting approach 
for cancer prevention (Ruiz-Larrea et al., 1997).  
Overall, it is clear that when evaluating biological effects of isoflavones it is necessary to 
look beyond the estrogen receptor and consider their non-hormone-related activities 
(Messina et al., 2001).  
4.2.3 Dose-dependent effects  
Soy isoflavones can induce different effects on breast cancer cells according to the dose used. 
For example, the effects of soy isoflavones in MCF-7 and BT20 breast cancer cells were only 
observed in the highest dose tested (50 µg/mL) (Theil et al., 2010). Similar effects were 
reported showing that isoflavone doses higher than 10 μM could inhibit the growth of breast 
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cancer cells (Wang et al., 1996). In particular, the IC50 values of genistein able to induce 
growth arrest in both hormone-dependent and hormone-independent breast cancer cells 
have been described to range from 10 to 50 µM (Messina et al., 2001).  
Some researchers question the relevance of these results by claiming that the high isoflavone 
concentrations used in vitro would not be achieved after ingestion in an in vivo system. Most 
Asians or Caucasians that consume a diet rich in soy have serum genistein levels smaller 
than 1 μM (Bouker et al., 2000). In order to address these claims, several assays evaluated 
the effects of isoflavones in low concentrations and, surprisingly, showed a different 
outcome. Low doses (0.01–1 μM) of genistein were shown to stimulate proliferation in 
human breast cancer cell lines (Bouker et al., 2000; Messina et al., 2001).  
In animal studies, soy isoflavones also induce different activities according not only to the 
dose but to the animal model and the route of administration used (Barnes et al., 1997). 
Injections of 0.8 mg genistein in rats significantly reduced MNU-induced tumor multiplicity 
and marginally reduced tumor incidence. Similarly, a high dose of daidzein (0.8 mg) 
decreased tumor multiplicity without affecting incidence, whereas a low dose (0.4 mg) was 
ineffective. Other study showed that rats fed with a low dose of biochanin A (10 mg/kg), 
which is an isoflavone that is converted to genistein in vivo, significantly reduced tumor 
multiplicity and that a higher dose (50 mg/kg) also reduced tumor incidence (Barnes et al., 
1997).  
Conversely, instead of decreasing tumor growth as previously commented, soy isoflavones 
have also been described to stimulate breast tumor growth in vivo (Helferich et al., 2008; 
Bouker et al., 2000; Allred et al., 2004). The effects of dietary level of genistein were studied 
in an athymic BALB/c ovariectomized mice model subcutaneously injected with human 
estrogen-dependent cells (MCF-7).  They found that in mice fed with a standard (control) 
AIN-93G diet, tumors reduced completely; however, mice fed with diets containing either 
isoflavone-rich isolated soy protein or isoflavone extracts had tumor growth stimulated 
(Hsieh et al., 1998). The use of a non-ovariectomized athymic mice model injected with ER-
negative breast cancer cells to evaluate the effects of high dietary levels of soy isoflavones 
intake showed that daidzein increased while genistein decreased mammary tumor growth 
by 38 and 33% respectively. In addition, daidzein increased lung and heart metastases while 
genistein decreased bone and liver metastases. Combined soy isoflavones did not affect 
primary tumor growth but increased metastasis to all organs tested, which include lung, 
liver, heart, kidney, and bones (Martinez-Montemayor et al., 2010). 
In general, the evidences indicate that at lower concentrations isoflavones exert estrogen-
like effects while at higher concentrations other non-estrogen receptor–mediated effects are 
induced (Messina et al., 2001). Data from in vivo studies suggest that in a low-estrogen 
environment (as exists in postmenopausal women), genistein is estrogenic and has a 
proliferative effect on breast tissue. However, in a high estrogen environment (similar to 
that in premenopausal women), it has an antiproliferative and possibly antiestrogenic effect 
(Hsieh et al., 1998; Allred et al., 2004). Therefore, isoflavones can both inhibit or stimulate 
proliferation of breast cancer cells showing a biphasic effect according to the dose (Bouker et 
al., 2000).  
Several hypothesis and discussion about experimental models limitations/weaknesses have 
been elaborated to address these conflicting results (Messina et al., 2008). First, considering 
that both estrogen and soy isoflavones bind to ER, differences in endogenous estrogen levels 
may interfere in the results. Premenopausal women have high levels of estrogen while basal 
levels of estrogen are found in postmenopausal women. Thus, in vitro estrogen-depleted 
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conditions and ovariectomized animals (with no basal estrogen levels) would not be suitable 
models because there are no sufficient estrogen levels to promote or even to maintain 
estrogen-dependent tumors. Even weak estrogenic compounds, such as isoflavones, could 
stimulate the growth of estrogen-sensitive mammary tumors in such environment (Messina 
et al., 2006). Thus, these models would not accurately reflect conditions in either 
premenopausal or postmenopausal women (Messina et al., 2008). Researchers have 
supported this hypothesis showing that although genistein stimulated proliferation of MCF-
7 cells and enhanced expression of the estrogen-responsive pS2 gene in an estrogen-
depleted in vitro environment, it inhibited estrogen-induced proliferation and reduced pS2 
expression of MCF-7 breast cancer cells when in the presence of a maintained level of 
estrogen (Wang et al., 1996; So et al., 1997). Nevertheless, breast tumor growth stimulation 
by both dietary and subcutaneously injected genistein has still been noted in animal models 
in which estrogen levels were more similar to the amounts of pre and postmenopausal 
women (Messina et al., 2006).  
The second critique addresses the use of mice lacking the immune properties (athymic or 
nude). This animal feature is a necessary element of these models in order to allow the 
growth of human tumor cells in a murine environment. However, the lack of immune 
function may eliminate a potential mechanism by which soy isoflavones reduce tumor 
development (Messina et al., 2008). A recent research in B6C3F1 mice showed that enhanced 
immune function resulting from pre-treatment with genistein (20 ppm) is correlated with 
protection against chemically-induced mammary tumors (Guo et al., 2007).  
The third critique relates to isoflavone dose. In many studies, breast cancer cells and animals 
are exposed to high amounts of genistein (750 ppm) which exceeds typical dietary intake. In 
Japan, adults consume about 15–20 mg genistein daily (total average isoflavone intake is 
approximately 40 mg), which equates to a dietary concentration of about 30–40 ppm 
(Messina et al., 2008). However, it is important to highlight that isoflavone biodistribution is 
not homogeneous. Isoflavone concentrations in breast tissue are two- to threefold higher 
than paired serum concentrations. It suggests that breast tissue may be exposed to higher 
levels of biologically active isoflavones than was previously thought (Pasqualini et al., 2005) 
and supports investigations of high concentrations of isoflavones. 
Another aspect of oral doses of isoflavones relies in the amount of free (unconjugated) 
isoflavones processed by intestinal bacteria. The rodent gut bacteria are able to convert 
daidzein to the metabolite equol more effectively than humans. Furthermore, even in 
humans who are classified as equol producers, genistein is the predominant serum 
isoflavone in response to the ingestion of soy or mixed isoflavones, whereas equol 
predominates in most other species, including both rodents and monkeys (Gu et al., 2006). 
The fourth consideration is based on the fact that it is not clear to what extent the existing 
MCF-7 xenoplants in nude mice resemble tumors in human breast cancer. These tumors are 
fully transformed and composed of cells that are extremely sensitive to the growth-
stimulating effects of estrogen (Messina et al., 2008). Thus, a better comprehension of the 
current existing animal models and the development of new ones would contribute to the 
interpretation and translation of isoflavone effects in humans.   
Given the conflicting data and limited in vitro and in vivo models, the controversy about the 
effects of isoflavones either from soy foods or supplements would be unlikely solved by 
additional animal research (Messina et al., 2009). Then, epidemiologic data should be 
another alternative to study and conclude about isoflavone intake and breast cancer. 
Current data discussing this topic is provided in the next section.  
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4.2.4 Aspects of isoflavone intake in humans 
Women with high risk of breast cancer, breast cancer patients and survivors are among the 
group of consumers who have embraced soy products, isoflavone supplements and 
isoflavone-enriched foods, seeking for their health-promoting properties. Nevertheless, the 
estrogenic/antiestrogenic effects of these molecules and the disparities of in vitro and in vivo 
data have led to considerable controversy and misinterpretation among health professionals 
and consumers over the use of soy by this group of women. Due to the phytoestrogenic 
nature of isoflavone, several oncologists often discourage and even prohibit its intake by 
breast cancer patients, particularly those with ER-positive tumors (Messina et al., 2001). 
As previously discussed, early epidemiologic studies have reported that high isoflavone 
intake was related to low cancer rates regardless of intrinsic genetic and biological differences 
among populations worldwide (Wu et al., 1996). Since then, more researchers have attempted 
to refine the knowledge of this matter and further investigate the correlations of isoflavone 
intake among breast cancer biomarkers, time of exposition, and age. 
Soy intake was found to be significantly associated with a decreased risk of death from 
breast cancer and/or recurrence when evaluated in 5,042 Chinese women aged from 25 to 
75 followed for 5 years (Shu et al., 2009). These benefits remained significant even after 
adjusting the results for 17 factors including tumor, node, metastasis stage, ER, progesterone 
receptor status and the type of treatment received. It was also observed that women who 
had the highest level of soyfood intake and did not take tamoxifen had a lower risk of 
mortality and a lower recurrence rate than women who had the lowest level of soyfood 
intake and used tamoxifen (Shu et al., 2009; Messina et al., 2010). The association of 
decreased breast cancer risk and soy isoflavone intake has been observed even in Asian-
American women, both pre- and postmenopausal, living in the West (Wu et al., 1996). 
Overall, evidences show that for Asian women the risk of developing breast cancer reduces 
as soy intake rises. Even a soy intake of as little as 10 mg per day was sufficient to decrease 
breast cancer risk by 12% (Patisaul et al., 2010). 
Effects of isoflavone intake have also been investigated in non-Asian populations. In a US 
study, it was observed that breast cancer survivors (n= 1,954; followed for 6.3 years) had 
reduced risk of cancer recurrence with increasing amounts of isoflavone among 
postmenopausal women and tamoxifen users. Interestingly, more pronounced effects were 
observed in women with ER-positive breast cancer (Guha et al., 2009). Beneficial effects of 
isoflavone intake were also observed in a Dutch study, which compared serum isoflavone 
concentrations in women with and without breast cancer. It was observed that high plasma 
concentrations of genistein were associated with a 32% reduction in breast cancer risk 
(Verheus et al., 2007). Furthermore, it was reported that isoflavone intake was associated 
with a reduced risk of all-cause mortality during the 5-y follow-up period among 
postmenopausal U.S. breast cancer patients (Fink et al., 2007). 
Conversely, other investigations have failed in detecting benefits in soy isoflavone intake. 
One of them did not find significant differences in soy daidzein or genistein intake between 
breast cancer cases and their controls in Shanghai (Zheng et al., 1999). Other investigation 
showed that soy food intake was unrelated to survival of Chinese breast cancer patients 
during the 5.2-y follow-up period (Boyapati et al., 2005). Several other researchers have also 
suggested that soy consumption is not associated with a reduced risk of breast cancer; 
however, no harmful effects were found in these studies (Bouker et al., 2000).  
Breast tissue density has been used as a non-invasive breast cancer biomarker to evaluate 
isoflavone intake. It was observed that both intervention and epidemiologic studies have not 
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shown evidence of neither harm or benefit of isoflavone on breast cancer density (Messina et 
al., 2006). Analysis of breast cell proliferation has also been used as a biomarker of potential 
tumor promotion. Comparison of biopsies taken before and after exposure to soy products 
did not show increased cell proliferation in any of the four different trials involving breast 
cancer patients, healthy subjects, and women undergoing breast biopsy or definitive surgery 
for breast cancer. Daily isoflavone intake in these trials ranged from 36 to more than 100 mg, 
with study periods ranging from 2 weeks to one year (Messina et al., 2009). Another study 
examining more than one breast cancer biomarker found no statistically significant 
differences in cell proliferation (Ki67 index), histology (hyperplasia with or without atypia), 
or ER expression in 6 and 12 months of soy intake (Messina et al., 2006). Conversely, a study 
evaluating the effects of soy consumption (38 g soy protein isolate, 80 mg isoflavones) over 5 
months showed an association of  isoflavone intake and a two- to sixfold increase in breast 
nipple aspirate fluid (NAF) secretion of premenopausal but not postmenopausal women 
(Petrakis et al., 1996).  
The effects of isoflavone intake in serum estrogen and androgen levels have been widely 
investigated. The consumption of textured vegetable (i.e., soy) protein for 2 weeks elicited 
an ER-mediated response detected by increased pS2 levels (protein expressed in response to 
estrogen) in breast biopsies taken from premenopausal women (Hargreaves et al., 1999). 
However, high levels of soy products have been described to induce no changes or even 
decrease plasma estradiol concentrations in premenopausal women. None of these effects 
were observed in postmenopausal women (Bouker et al., 2000). These contrasting findings 
could be partially explained by the observation that, despite binding to ERs, isoflavones are 
also able to inhibit enzymes related to estrogen synthesis and metabolism. Therefore, it has 
been hypothesized that the presence of other additional simultaneous stimuli may result in 
either reduced or increased circulating estradiol concentrations (Bouker et al., 2000). 
Isoflavone intake has been implicated to interfere in serum levels of other menstrual cycle 
hormones, such as progesterone. Studies have reported that isoflavone intake was 
associated with a significant reduction in serum progesterone levels and in luteal phase 
lengths (Lu et al., 2000). These findings suggest that isoflavones may reduce the probability 
of neoplastic transformation and breast cancer development since breast cells are more 
proliferative during the luteal phase of the menstrual cycle, when progesterone 
concentrations are the highest (Lu et al., 2000). 
Overall, inconsistent results about isoflavone intake and breast cancer are also present in 
epidemiological studies. Indeed, researchers have highlighted the difficulties of comparing 
clinical studies since several variables are not properly considered. In a meta-analysis by 
Trock et al., 18 studies (12 case-control and 6 cohort) published between 1978 and 2004 were 
evaluated. After making several assumptions, the authors showed that there is a small 
inverse correlation between soy intake and breast cancer for both pre- and postmenopausal 
women; however data limitations cannot exclude the possibility that this result could be an 
artifact of the analysis (Trock et al., 2006).  
An important variable to be considered when evaluating risks and benefits of soy isoflavone 
intake comprises the extent and the period of life in which women are exposed to soy food. 
Studies attempting to address this topic are discussed in the next section.   
4.2.5 Lifetime exposition of isoflavones 
Throughout the life span, estrogens can induce mammary cell proliferation or cell 
differentiation depending on the overall hormonal environment. Since isoflavones present 
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estrogenic or antiestrogenic activities, they may have a different impact on the breast if the 
exposure occurs in utero; during childhood, puberty, or pregnancy; premenopausally; or 
during postmenopause (Bouker et al., 2000). Studies have been carried out to determine if 
the putative preventive effects of soy isoflavones are related to the lifetime period of 
exposition. 
Different outcomes have been shown from perinatal/neonatal exposure of isoflavones in 
animals. The offspring of pregnant rats receiving subcutaneously administration of high 
doses of genistein exhibited abnormal mammary gland development and higher 
susceptibility to develop  7,12-dimethylbenz[a]anthracene (DMBA)- induced mammary 
tumorigenesis (Padilla-Banks et al., 2006; Patisaul et al., 2010). Conversely, it was reported 
that rat pups born to mothers consuming high levels of genistein during gestation and 
lactation developed fewer breast tumors (Fritz et al., 1998). Protective effects of isoflavones 
were also reported when soy exposure occurred perinatally. Rats receiving genistein 
through diet or subcutaneously during the first days postpartum showed lower tumor 
incidence after DMBA mammary tumor induction (Lamartiniere, 2000).   
The period between puberty and a first full-term pregnancy is when the breast is 
particularly vulnerable to the effects of carcinogens. During this time, there are a high 
percentage of indiferentiated breast cells, named terminal end buds (TEBs), actively 
proliferating. Several investigations in animal models have shown protective effects of 
prepubertal isoflavone exposure on mammary tumorigenesis induced by DMBA (Murrill et 
al., 1996; Lamartiniere et al., 1998).  
Epidemiological studies support in vivo findings showing that isoflavone intake during 
adolescence and adulthood is correlated with low risk of breast cancer. Shu et al. reported 
that women consuming tofu (11 g soy protein/day) during their teenage years (13–15 years) 
were less likely to develop premenopausal and postmenopausal breast cancer as adults (Shu 
et al., 2001). Other epidemiologic studies have supported these results when protective 
effects with reductions in risk of breast cancer ranging from 28 to 60% were observed 
(Messina, 2010).  
Investigations on mammary gland morphology and cell differentiation were carried out in 
animal models to understand how isoflavone exerts the described protective effects. The 
results indicated that isoflavones might have been exerting its chemoprotective effect by 
stimulating early cell differentiation leading to a reduction in the number of least 
differentiated structures in the breast tissue (TEBs) which are susceptible to chemical 
carcinogens (Bouker et al., 2000; Lamartiniere, 2000).  
Therefore, animal and epidemiological studies are consistent with the hypothesis that 
childhood and/or adolescence is the critical period for isoflavone of exposure (Messina et 
al., 2006) and also corroborates with speculations that Asian low breast cancer rates is 
derived from early exposure to soy products, including during pregnancy (Lamartiniere, 
2000).  
4.2.6 Variables influencing inconsistent outcomes   
To better interpret and understand data about isoflavone intake and breast cancer it is 
important to consider the strengths and weaknesses of a wide variety of experimental 
models and designs (Messina et al., 2006). As commented previously, the major sources of 
limitation in those studies are the inappropriate experimental designs and incomplete or 
unclear information provided about food isoflavone content, patient description, serum 
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isoflavone levels, time of exposition, and isoflavone metabolism. There are studies in which 
some variables are not even considered. Differences in these factors can considerably 
difficult comparisons among studies generating misinterpretations of data and are probably 
related to the majority of inconsistent results in the literature.  
Epidemiologic studies should take into consideration that the amounts of isoflavones are 
not equal in all soy foods. Indeed, there are notably differences in soy food preparations and 
isoflavone content. Raw soybeans contain nearly 1.0 mg/g (range of 0.4 –2.4 mg/g of total 
isoflavones while traditional soy foods (i.e., tofu, miso, natto) typically contain 0.2– 0.4 
mg/g (Messina et al., 2001). In addition, the content and structure of isoflavones are altered 
when soy food undergo processing, which was shown to potentially affect the effects on 
breast cancer (Murphy et al., 1999; Allred et al., 2004).  
Moreover, soy isoflavone content can vary according to local, weather, seed maturation, and 
breeding conditions. It was observed that during the process of seed maturation the 
contents of isoflavones decrease, whereas sprouting led to a continuing increase of 
isoflavone content. Interestingly, the protein extracts from the developing seeds showed 
clearly opposite effects on cell viability and inhibition of foci formation compared with those 
from sprouting seeds (Park et al., 2005).  
Individual differences in the absorption and metabolism of ingested isoflavones are another 
variable not usually addressed on breast cancer studies. To evaluate the potential risks and 
benefits of phytochemicals to human health, it is important to know the physiological 
behavior of these compounds after ingestion (Hsieh et al., 2010). As previously commented, 
isoflavones are metabolized by intestinal microorganisms, which may be heterogeneous 
among individuals. This variability may have large contributing effects on the serum levels 
of free isoflavones and correspondent metabolites and thereby on the resulting physiologic 
effects. Furthermore, differences in isoflavone metabolism and bioavaiability should also be 
considered when analyzing data from rodent animal models since a higher percentage of 
both genistein and daidzein appear in the free or glycone form in rats (Gu et al., 2006). 
Individual variabilities should also be considered when analyzing the effects of isoflavone 
intake in estrogen and progesterone serum levels. Menstrual cycle length varies significantly 
among women and analysis of reproductive hormone levels in single periods may not 
provide accurate data on isoflavone effects. In this case, it would be more appropriate to 
measure the hormone levels during the whole menstrual cycle (Lu et al., 2000). Different 
times of isoflavone exposition are yet another type of limitation that influences data 
interpretation. For example, short periods of exposition (such as 2 weeks) may provide data 
regarding only the acute effects of soy isoflavone intake on breast cancer, thus, limiting 
comparisons with long-term studies.  
Other potential source of variability in clinical studies includes incomplete patient 
description. Different and more specific correlations would be obtained whether patients 
were also addressed in subgroups by ER status, serum estrogen levels, and type of 
treatment being received (e.g. tamoxifen) for example.  Those detailed patient information 
should also be used as valuable adjustment parameters for raw data in order to improve 
interpretation accurateness (Shu et al., 2009; Messina et al., 2010).  
Clearly, there is a need to encourage further detailed studies to reduce the heterogeneity of 
soy exposure data (Rochfort et al., 2007). Several recommendations have been made to 
improve study conditions and data interpretation such as: provide clear information about 
the isoflavone content (including glycone amount) on test products; include detailed 
description of products, concentrations, and amounts used; relate study conditions to usual 
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soy and isoflavone intakes and/or tissue levels of isoflavones; consider the risks and 
benefits of research findings for human health; and outline the benefits and limitations of 
the model system used when conducting cell culture or animal studies (Erdman et al., 2004). 
5. Protease Inhibitors 
5.1 Structure and bioavalability 
Protease inhibitors (PIs) have been isolated from black-eyed peas (Vigna unguiculata), soy 
(Glycine max), brazilian pink bean (Phaseolus vulgaris), pea (Pisum sativum) and lentil (Lens 
culinaris) (Losso, 2008). In seeds, these molecules are involved in the regulation of 
endogenous proteases and in defense-related strategies against seed-eating insects and 
microorganisms (Ryan, 1990). The concentration of PIs is affected by the stage of seed 
development and sprouting. For example, soy-derived BBI content increases during the 
process of seed maturation while it decreases with soaking time during sprouting (Park et 
al., 2005).  
PIs are classified in more than 20 families according to their inhibitory activity and 
structural features (Laskowski et al., 2000; Joanitti et al., 2006). The primary families found 
in legumes are the Kunitz and the Bowman-Birk which are involved in the inhibition of 
serine proteases (Joanitti et al., 2006; Losso, 2008). Kunitz PIs consist of proteins with 
molecular mass ranging from 6-20 kDa. These inhibitors are cross-linked by 2-3 disulfide 
bonds and have one reactive site that generally binds to trypsin. Bowman-Birk PIs are small 
proteins (6-15 kDa) presenting 5-7 disulfide bonds and 2 different and independent reactive 
sites located at opposite regions of the molecule (Fig. 2). Due to this double-headed 
configuration, these inhibitors can interact with 2 enzymes simultaneously (e.g. trypsin and 
chymotrypsin or trypsin and trypsin (Freitas et al., 1999; Ventura et al., 1966)). The disulfide 
bonds content of Kunitz and Bowman-Birk PIs are responsible for their remarkable 
structural stability (Joanitti et al., 2006). It has been reported that the inhibitory activity of 
these molecules is preserved after being exposed to a wide range of temperatures (up to 
100oC) and pHs (2-13) (Silva et al., 2001; Ho et al., 2008; Ye et al., 2009). 
 
 
Fig. 2. Tridimensional structure of the Black-eyed pea trypsin and chymotrypsin inhibitor 
(BTCI) (Barbosa et al., 2007); PDB access number 2G81) and Bowman-Birk inhibitor (BBI) 
(PDB access number 1BBI) in ribbon representation. The disulfide bonds (in green) and 
reactive sites for trypsin (Lys) and chymotrypsin (Phe or Leu) are indicated. The image was 
made with VMD (Theoretical and Computational Biophysics Group, NIH Resource for 
Macromolecular Modeling and Bioinformatics, Beckman Institute, University of Illinois, 
Urbana-Champaign). 
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Because Kunitz and Bowman-Birk PIs are involved in the inhibition of serine proteases, 
these molecules have been considered as antinutritional factors able to impair digestion. 
Proper thermal seed processing have been described to eliminate the majority of legume 
antinutritional factors (Lajolo et al., 2002); nevertheless, some Kunitz and Bowman-Birk PIs 
are able to resist both acidic conditions and the action of proteolytic enzymes and pass 
through the stomach and small intestine without major degradation (Clemente et al., 2010). 
The metabolism and absorption of a soy Bowman-Birk PI (termed BBI) have been well 
characterized following oral administrations. After ingestion, BBI are rapidly metabolized 
and absorbed. BBI can resist stomach and small intestine conditions permitting the reach of 
significant amounts to the large intestine in the active form to exert their reported anticancer 
and anti-inflammatory properties (Kennedy, 1998). This PI is widely distributed throughout 
the body including breast tissue (Kennedy, 1998). In mice, BBI metabolites can be found in 
the liver, serum, and kidneys of mice 1.5 hours after ingestion (Wang et al., 2000). In 
humans, BBI excretion rates reach the peak within 6 hours and decrease to baseline levels 
within 12-24 hours (Wan et al., 2000).  
PIs have been viewed as toxic agents inhibiting the growth of young animals and, perhaps, 
contributing to the development of pancreatic cancer. However, the effect on the promotion 
of atypical growth in rat pancreata, is not expected to occur in humans (Kennedy, 1998). 
Despite preserving their biological activity after passing through the gastrointestinal tract, it 
seems that these inhibitors do not act as antinutritional factors since they are not implicated 
in significant side effects even when ingested in concentrations far higher than the 
therapeutic dose (Kennedy, 1998). 
5.2 Effects on breast cancer 
PIs have been considered promising compounds in several economic and clinical areas. 
These inhibitors are multiple functional molecules with properties varying from insecticide 
to therapeutical activity in fields as immune systems, microorganism and viral infections, 
hemostasis, and cancer (Joanitti et al., 2006). PIs have shown promising anticancer effects on 
the prevention and suppression of cancer in several organ systems and tissue types (e.g. 
colon, liver, lung, esophagus, oral epithelium, ovarian, prostate, hematopoietic cells, and 
connective tissue), in vitro and in vivo (Kennedy, 1998). Particularly, BBI (Bowman-Birk 
Inhibitor from soy) was recognized as an investigational new drug by the Food and Drug 
Administration (FDA) and is currently being evaluated in clinical trials against pre-
malignant oral cancer lesions, showing successful results on the reduction of cancer lesions 
with low or no side effects (Armstrong et al., 2000). Despite having their anticancer activity 
being widely investigated on different tumor types, few studies have addressed the effects 
of Kunitz and Bowman-Birk PIs specifically on breast cancer. 
The effects of soy BBI on DMBA-induced transformation were investigated using an in vitro 
whole organ culture system of mouse mammary glands. It was observed that soy BBI and its 
palmitic acid conjugate (Pal-BBI) were effective in preventing DMBA-induced 
transformation, especially when added to the medium during the developing period after 
the exposure of mammary glands to DMBA, showing 35.9 and 53.4% prevention, 
respectively. Pal-BBI was also effective in decreasing the transformation incidence (32.2%) 
while BBI was not (10.3%) when only present in the medium before the promotion period. 
Possibly, the high lipophilicity of Pal-BBI increased its tissue retention and resulted in 
higher chemopreventive effects (Du et al., 2001). 
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An interesting in vivo study reported the effects of one year-long feeding of field bean meal 
(a rich source of PIs with 24% protein content), on mouse mammary tumor virus (MMTV)-
induced mammary tumorigenesis in mice. The animals were fed chow with 2%, 4%, and 8% 
field bean protein (FBP) for 49 weeks and the incidence of mammary tumors was recorded 
in 58 weeks. A suppressive effect on mammary tumorigenesis was observed with increased 
FBP intake as mice fed with 2%, 4%, and 8% FBP showed significant tumor incidence 
reduction of 68%, 75% and 81% respectively. Adverse growth effects were observed only in 
mice receiving the 8% FBP-fed group (Fernandes et al., 1997).  
In addition to chemopreventive properties, PI effects on the viability of breast cancer cells 
have also been reported. A Bowman-Birk PI isolated from Hokkaido large black soybeans 
seeds and a Kunitz PI isolated from Chinese black soybean seeds have been described to 
suppress the proliferation of breast cancer cells (MCF-7) in vitro (Ho et al., 2008; Ye et al., 
2009). Similar effects were observed in MCF-7 cells treated with Bowman-Birk PIs derived 
from soy or black-eyed peas (Zhang et al., 1999; Joanitti et al., 2010). Conversely, it was 
described that soy BBI was not able to induce anticancer effects on ER-negative breast cancer 
cell MDA-MB 231 (Hsieh et al., 2010). It has been suggested that additional investigations 
should be made to determine whether tumor cell types and their specific carcinogenesis 
pathways may be determinants of the cancer chemopreventive properties of BBI (Hsieh et 
al., 2010).  
PIs have been described to act on different cancer stages and activities impairing malignant 
cell transformation, altered gene expression and proteolytic activity, tumor growth, 
angiogenesis, and metastasis. These effects have been suggested to be linked to their 
protease inhibition activity (Kennedy, 1998; Joanitti et al., 2006). Nevertheless, the precise 
mechanisms by which PIs exerts their preventive and suppressive anticancer effects are not 
completely elucidated on breast cancer.  
One of the main effects observed in tumor cells treated with PIs is a reduction on cell 
proliferation rates (Wan et al., 1998; Zhang et al., 1999; Chen et al., 2005). In 2005, Chen et al. 
reported a landmark research study revealing some clues about the mechanisms involved in 
this growth inhibition. They observed that the soy-derived BBI was able to inhibit 
proteasome activity, specifically the chymotrypsin-like domain, in vitro and in vivo in MCF-7 
breast cancer cells. Proteasomes are large protein complexes acting in the degradation of 
misfolded proteins and regulation of particular proteins levels involved in intracellular 
pathways. Proteasome inhibition by BBI resulted in an accumulation of ubiquitinated 
proteins and proteasome substrates, such as cell cycle inhibitors p21Cip1/WAF1 and 
p27Kip1, inducing cell cycle arrest at G1/S phase. Furthermore, an up-regulation of MAP 
kinase phosphatase-1 (MKP-1) accompanied by a decrease of phosphorylated extracellular 
signal-related kinases (ERK1/2), which is a pathway involved in cell division, was also 
observed (Chen et al., 2005).  
In addition to tumor growth inhibition, the BBI found in black-eyed peas (termed BTCI) was 
also shown to induce death on MCF-7 cells (Joanitti et al., 2010). The treatment of cells with 
BTCI induced significant reduction of the cell proliferation (arrest in S and G2/M phase) 
accompanied by significative DNA fragmentation, mitochondrial swelling, morphologic 
alterations, annexin-V+ cell number increase, and mitochondrial membrane potential 
reduction. These cytotoxic effects at first suggested that BTCI induced apoptosis cell death 
on MCF-7 cell. However, other features observed such as large lysosomes presenting weak 
acidification pattern followed by an increase in cytoplasmic acidification indicated another 
cell death pathway related to lysosomes: the lysosomal membrane permeabilization (LMP). 
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LMP is characterized by a perturbation of lysosomal membrane function leading to the 
translocation of lysosomal hydrolases from the lysosomal lumen to the cell cytoplasm. 
Therefore, the authors suggested that BTCI was able to induce both LMP and apoptosis 
processes on breast cancer cells (Joanitti et al., 2010). 
The ability to induce tumor growth inhibiton and or cell death might be determined by PIs 
structural features, especially on the reactive sites, leading to different affinities to the 
targets. Moreover, variations in the dose and time of exposure are also important factors to 
be considered. For example, low Bowman–Birk PIs concentrations (10–40 µM) and long 
incubation periods (6–14 days) are frequently associated with proliferation inhibition (Wan 
et al., 1998; Zhang et al., 1999); while high concentration (200 µM) and short incubation 
periods (3 days) has been described to induce both tumor growth inhibition and cell death 
(Joanitti et al., 2010). Overall, these findings indicate that PIs are promising anticancer 
molecules and encourage more studies of these compounds on breast cancer. 
6. Peptides 
6.1 Structure and bioavailability 
Among bioactive peptides found in legumes, a peptide isolated from soybean cotyledon has 
stand out as a potential anticancer agent. Lunasin is a 43-amino acid peptide with 
structurally conserved helix region containing Arg- Gly-Asp (RGD) cell adhesion motif 
followed by 9 aspartic acid residues at the carboxyl end. This peptide exhibits the  
primary sequence, SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD 
(Hernandez-Ledesma et al., 2009). 
Lunasin has been identified in several soybean varieties with concentrations ranging from 
4.4 to 70.5 mg lunasin/g protein (Gonzalez de Mejia et al., 2004; Hernandez-Ledesma et al., 
2008). These concentrations are affected by the stage of seed development and sprouting. A 
notable increase of lunasin content is observed during seed maturation while the opposite 
occurs during sprouting. Breeding conditions (light and dark cycles) do not seem to affect 
the content of this peptide (Park et al., 2005). Large-scale processing of soy also influences 
lunasin concentration which was observed to vary from 12 to 44 mg lunasin/g of flour 
among different U.S. commercially available soy proteins (Gonzalez de Mejia et al., 2004).  
Besides presenting heat stability, in vitro digestibility studies have shown that lunasin is 
digested by pancreatin (Galvez et al. 2001). However, animal studies indicate that when 
lunasin is ingested in combination with soy protein extract, it survives digestion and about 
35% of the total oral dose is absorbed within 3 hours (de Lumen, 2005). These findings 
suggest that other components of soy are protecting lunasin from degradation (see section 
7). Lunasin is biodistributed in various tissues including lung, liver, mammary gland, 
prostate and even the brain within 6 hours after administration. In addition, analysis of the 
liver and blood showed that this peptide was present in an intact and bioactive form (Jeong 
et al., 2007; Hsieh et al., 2010). 
6.2 Effects on breast cancer 
Lunasin was first discovered during studies regarding soy seed development. Early soybean 
seed development is characterized by orchestrated events of rapid cell division and 
differentiation. It was observed that the stage of seed cell expansion (massive synthesis of 
storage molecules) began after cell division had ceased and that a temporal production of 
lunasin coincided with this mitotic arrest. This data led to the hypothesis that lunasin could 
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also be involved in the disruption of mammalian cell division such as cancer cells. Indeed, 
lunasin was shown to block mitosis in mammalian cells by binding to chromatin and 
impairing the formation of the kinetochore complex in the centromere. These effects lead to 
the failure of microtubules to attach the centromeres and thereby to mitotic arrest and cell 
death (Galvez et al., 1999). 
The mechanism of action for lunasin in the prevention of cell malignant transformation is 
related to chromatin binding. The dynamics of histone acetylation and deacetylation in non-
cancerous cells is involved in chromatin remodelling which is implicated in cell cycle 
control (Hernandez-Ledesma et al., 2009). These processes are tightly regulated by tumor 
suppressor molecules which have among other activities the function to keep the histone 
core in a deacetylated (repressed) state. Nevertheless, during cell malignant transformation, 
many tumor suppressor molecules are inactivated by chemical and viral carcinogens which 
lead to the exposure of histones core. At this stage, lunasin is able to inhibit histone 
acetylation by binding deacetylated histones which prevents transcription and represses cell 
cycle progression (Galvez et al., 1999; Hernandez-Ledesma et al., 2009). In this context, 
lunasin can act as a surrogate tumor suppressor. Therefore, it has been suggested that 
lunasin selectively kills cells that are being transformed by disrupting the dynamics of 
histone acetylation-deacetylation when a transforming event occurs (Hernandez-Ledesma et 
al., 2008). 
The RGD motif also contributes to the anticancer effects of lunasin. Since RGD motif is 
implicated in the attachment of tumor cells to the extracellular matrix, peptides containing 
this motif have been described to prevent metastasis of tumor cells by competitive adhesion 
to the extracellular matrix. Furthermore, it has been suggested that the internalization of 
lunasin in MCF-7 cells would be mediated by a functional RGD motif (Galvez et al., 1999). 
In in vitro studies, lunasin was shown to suppress colony formation induced by the ras-
oncogene in MCF-7 cells (Jeong et al., 2003). The in vivo effects of lunasin were investigated 
on an ER-negative MDA-MB-231 breast cancer model in which athymic mice received 
intraperitoneal injections of lunasin (4 or 20 mg/kg body weight) for 2 months prior to 
tumor implantation. After 7 weeks, mice treated with lunasin showed a significant reduction 
in breast tumor incidence and a delay in the appearance of tumors. In addition, histologic 
analysis revealed low proliferation and high apoptosis indexes in tumors of lunasin-treated 
mice (Hsieh et al., 2010). 
7. Combined effects of bioactive compounds  
The combination of therapies has emerged as an interesting approach for cancer prevention 
and treatment. This alternative strategy is based on synergistic effects of 2 or more 
anticancer compounds able to act in multiple targets resulting in a more efficacious 
treatment. Moreover, the combination of agents can result in significant activity at 
concentrations where the single agent is inactive. Thus, there is possibility to regulate an 
optimal dose and reduce unwanted side-effects (Lane, 2006). 
As extensively commented here, legumes are rich sources of anticancer compounds 
including not only isoflavones, protease inhibitors and peptides but also saponins, phytic 
acid, and inositol phosphates. These molecules have different mechanisms of action on 
cancer cells, which suggests that their combination would result in synergistic effects. For 
example, a soy extract containing isoflavones and saponins significantly reduced the 
incidence of mammary tumour induced by DMBA (Gallo et al., 2001; Jin et al., 2002).  
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Inhibition of both breast tumor growth and metastasis was observed in animals treated with 
isolated soy proteins and isoflavones (Yan et al., 2002). Supplementation of isoflavone-
containing crude soy protein to a transgenic mouse model for mmammary tumor 
significantly prolonged the latency period of tumour development (Jin et al., 2002). 
The effects of combining legume bioactive compounds with other dietary molecules have 
also been studied. The combination of soy phytochemicals at a low dietary level with tea 
showed synergistic effects on inhibiting the growth of MCF-7 tumours (Zhou et al., 2004). 
Velie et al. undertook a large diet-based cohort study (40,559 postmenopausal women) and 
found that the only diet with significant negative correlation with invasive breast cancer 
was the traditional southern diet, which comprises high legume intake, low mayonnaise 
intake, and potentially cabbage intake (Velie et al., 2005).  
The potential synergisms among legume bioactive compounds provide a clue to explain the 
different effects observed between studying the bioactive compound alone and evaluating a 
specific bioactive compound often associated with other anticancer molecules present in the 
legume. Therefore, researchers should consider the characterization of each legume extract 
or food not only in terms of quantity of the studied molecule but also in terms of identifying 
the presence of other potential bioactive compounds. This approach should improve data 
quality and allow more reliable comparisons and conclusions regarding the benefits and 
risks of legume intake.   
In addition, the elucidation of these synergistic mechanisms may be useful to clarify the real 
effect of each bioactive compound and, based on this knowledge, aid in the design of novel 
preventive/therapeutic approaches and dietary guidelines. Chiesa et al. compared the 
breast tumor development of mice receiving a diet with different concentrations of 
isoflavones and soy protein and concluded that only animals receiving an isoflavone-poor 
soy protein concentrate diet showed reduction in tumor progression rates and metastasis 
development (Chiesa et al., 2008). Another study aimed to elucidate the synergistic effects 
between the major bioactive components present in a soy extract termed “Bowman-Birk 
Inhibitor Concentrate” (BBIC). BBIC was developed for use in large-scale human cancer-
prevention trials and has been extensively studied for its bioactivity against several cancer 
types (Kennedy, 1998). Its anticancer effects have been mainly attributed to the soy-derived 
BBI, which is present in high concentrations in this extract (Kennedy, 1998). In addition to 
BBI, lunasin peptide is also present and both represent 44% of total protein in BBIC. BBI and 
lunasin peptide were administered intraperitoneally and separately in mice for 2 months 
prior to the implantation of MDA-MB-231 breast cancer cells. Surprisingly, it was observed 
that only lunasin was effective in inducing significant chemopreventive and therapeutic 
effects. In this context, BBI and other PIs present in BBIC complement lunasin activity in 
other manner. Since lunasin is easily degraded by gastrointestinal enzymes when ingested 
in a pure form, it has been reported that those PIs protect lunasin from digestion and make 
this peptide bioavailable (Hsieh et al., 2010). 
Approaches of combining legumes bioactives compounds with conventional 
chemotherapeutic drugs have been shown promising results. Ito et al. reported that the 
combination of 10% miso diet (soy food) with 2.5 mg/kg tamoxifen resulted in a significant 
reduction in the incidence and multiplicity of MNU-induced mammary carcinomas mice 
(Ito et al., 1996). The combination of tamoxifen and soy protein isolate provided a better 
protection than using the components alone. The tumor incidence in DMBA-induced 
mammary carcinogenesis mice was reduced 29% by tamoxifen, 37% by soy protein isolate 
and 62% by the combination (Constantinou et al., 2001).  
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The high intake of soy isoflavones was associated with reduced risk of ER-positive breast 
cancer recurrence in patients receiving anastrozole treatment (aromatase inhibitor). In 
addition, it was suggested that the observed effect might be related to a synergistic 
inhibitory effect of isoflavones and anastrozole on the synthesis of estrogen (Kang et al., 
2010). Another interesting combination with centchroman (selective estrogen receptor 
modulator) and soy intake was investigated on DMBA-induced mammary carcinogenesis. 
The doses and periods of treatment were optimized and a maximum tumor regression of 
98.6% were achieved with centchroman 5 mg/kg per day, alone/in combination with soy 
3×104 mg/kg per day at 5 weeks treatment period (Mishra et al., 2010).  
8. Conclusion  
Undoubtedly, plant species are notable sources of compounds essential to human health not 
only in terms of nutrition but also in a therapeutic aspect. In particular, the variety of 
legume-derived bioactive compounds has attracted the attention of researchers for their 
health-promoting properties on breast cancer. Encouraging results have identified the 
preventive and treatment effects of these compounds on breast cancer in in vitro, in vivo and 
epidemiological studies. However, other data sets indicate harmful or neutral outcomes. 
Therefore, the discussed data do not allow conclusive statements regarding the effects of 
legumes and their bioactive compounds on humans, especially on women at high risk for 
breast cancer and breast cancer patients. 
Re-evaluation of current data and further studies are crucial to elucidate such doubts. 
Nevertheless, in order to provide expressive contributions and to make studies comparable, 
the design and interpretation of new experiments should be considered. In this context, the 
influences of variables, such as dose and time of exposition, and potential synergisms or 
antagonisms among compounds need to be investigated. Indeed, further studies on the 
effects and mechanisms of action of these molecules on breast cancer will provide a better 
comprehension regarding the safety of legume intake and the elaboration of suitable dietary 
guidelines.  
The conclusive characterization of legumes as preventive and therapeutic anticancer 
compounds would lead to interesting future perspectives. Among other options, it would be 
possible to develop therapies based on legumes compounds; to improve their bioavailability 
by the use of drug delivery systems; to use them as templates in the process of rational 
design of new anticancer drugs; and even to control the amounts of specific bioactive 
compounds produced by genetically engineered legume crops.  
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